Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Ticagrelor versus prasugrel in patients with acute myocardial infarction

Authors
Park, SangwooKim, Yong-GiunAnn, Soe HeePark, Hyun WooSuh, JonRoh, Jae-HyungCho, Young-RakHan, SeungbongPark, Gyung-Min
Issue Date
1-12월-2021
Publisher
ELSEVIER IRELAND LTD
Keywords
Myocardial infarction; Ticagrelor; Prasugrel; Percutaneous coronary intervention
Citation
INTERNATIONAL JOURNAL OF CARDIOLOGY, v.344, pp.25 - 30
Indexed
SCIE
SCOPUS
Journal Title
INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume
344
Start Page
25
End Page
30
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/140198
DOI
10.1016/j.ijcard.2021.09.063
ISSN
0167-5273
Abstract
Background: Ticagrelor and prasugrel are the mainstay of antithrombotic therapy for patients with acute myocardial infarction (MI). However, direct comparative data on clinical outcomes of potent P2Y12 inhibitors are limited, especially in East Asian populations. We aimed to evaluate the effect of ticagrelor versus prasugrel on clinical outcomes in patients with acute MI. Methods: From the Korean nationwide National Health Insurance database, 10,797 patients with acute MI who received either ticagrelor or prasugrel in combination with aspirin after percutaneous coronary intervention (PCI) were enrolled. The primary outcome was net clinical benefit, defined as a composite of death, MI, stroke, or major bleeding. Secondary outcomes included the individual components of the primary outcome as effectiveness and safety measures. Results: Among 10,797 patients, 9591 (88.8%) received ticagrelor and 1206 (11.2%) received prasugrel. During a median follow-up of 1.8 years, the primary outcome occurred in 1051 (16.6%) and 131 (14.4%) patients in the ticagrelor and prasugrel groups, respectively. In the propensity score matched cohort (n = 5979), the risk for the primary outcome was similar between the two groups (hazard ratio [HR] 0.949 for prasugrel; 95% confidence interval [CI]: 0.780-1.154). The risks for the composite of death, MI, or stroke (HR 0.938; 95% CI: 0.752-1.169) and major bleeding (HR 1.022; 95% CI: 0.709-1.472) were also comparable. Conclusions: In patients with acute MI undergoing PCI, ticagrelor and prasugrel appeared to have similar net clinical benefits. The risks for death, MI, or stroke and major bleeding were not significantly different between the two groups.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE